Suppr超能文献

DR4/JNK 通路介导致肝癌细胞获得性 TRAIL 耐药中的自噬作用。

Involvement of DR4/JNK pathway-mediated autophagy in acquired TRAIL resistance in HepG2 cells.

机构信息

Department of Pathology, College of Medicine, Chosun University, Gwangju 61501, Republic of Korea.

Division of Premedical Science, College of Medicine, Chosun University, Gwangju 61501, Republic of Korea.

出版信息

Int J Oncol. 2016 Nov;49(5):1983-1990. doi: 10.3892/ijo.2016.3699. Epub 2016 Sep 20.

Abstract

Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent, a number of cancer cells demonstrate TRAIL resistance. To date, various molecular targets leading to TRAIL resistance have been elucidated by many researchers, but the mechanisms involved are still not fully understood. In the present study, we obtained TRAIL-resistant cells from the human hepatocellular carcinoma cell line HepG2 by exposing cells to recombinant human TRAIL (rhTRAIL), and determined a mechanism for TRAIL resistance. The selected TRAIL-resistant cells (HepG2-TR) were insensitive to rhTRAIL and triggered autophagy in response to rhTRAIL. The inhibition of autophagy by 3-methyladenine or the knockdown of ATG5 partially restored rhTRAIL-induced apoptosis and cytotoxicity, indicating that protective autophagy occurred in the cells. Notably, rhTRAIL-induced autophagy was mediated through DR4 in HepG2-TR cells, but not in parental HepG2 cells. In addition, the c-Jun N-terminal kinase was involved in DR4-mediated autophagy in HepG2-TR cells. Our results suggest a novel mechanism of TRAIL resistance which is regulated through alterations in DR4 function, which may extend our understanding of the mechanisms of TRAIL resistance.

摘要

虽然肿瘤坏死因子相关凋亡诱导配体(TRAIL)是一种很有前途的抗癌药物,但许多癌细胞对 TRAIL 表现出耐药性。迄今为止,许多研究人员已经阐明了导致 TRAIL 耐药性的各种分子靶点,但涉及的机制仍不完全清楚。在本研究中,我们通过用重组人 TRAIL(rhTRAIL)处理细胞,从人肝癌细胞系 HepG2 中获得了 TRAIL 耐药细胞,并确定了 TRAIL 耐药的机制。选择的 TRAIL 耐药细胞(HepG2-TR)对 rhTRAIL 不敏感,并对 rhTRAIL 触发自噬。用 3-甲基腺嘌呤抑制自噬或敲低 ATG5 部分恢复了 rhTRAIL 诱导的细胞凋亡和细胞毒性,表明细胞中发生了保护性自噬。值得注意的是,rhTRAIL 诱导的自噬是通过 HepG2-TR 细胞中的 DR4 介导的,但在亲本 HepG2 细胞中则不是。此外,c-Jun N-末端激酶参与了 HepG2-TR 细胞中 DR4 介导的自噬。我们的结果表明了一种 TRAIL 耐药的新机制,该机制通过改变 DR4 功能来调节,这可能有助于我们进一步理解 TRAIL 耐药的机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验